From time to time, Mayo Clinic or a Mayo Clinic physician may have a financial interest in an invention, technology, company or product mentioned in the Health Letter. Below is a full list of financial disclosures.
- Dr. Jay Smith, a reviewer of our July 2019 article on plantar fasciitis, has a financial interest in the ultrasonic fasciotomy and debridement product referenced in the article.
- Dr. Mark Spangehl, a reviewer for our November 2019 article on hip preplacement, receives research support from implant companies that manufacture hip replacements.
- Dr. Greta Stamper, a reviewer of our December 2019 article on hearing aids, recommends hearing aids for purchase to patients, but as a salaried employee is not financially rewarded for sales.
- Dr. Landon Troost, a reviewer of our December 2019 article on Peyronie's disease, was the inventor of the RestoreX device mentioned in the article. However, he does not have any formal role or affiliation with the company, and is not an investor.
- Dr. Shaji Kumar, a reviewer for our March 2020 article on multiple myeloma, receives research support directed through Mayo Clinic from the following sources: Celgene, Takeda, Janssen, BMS, Sanofi, KITE, Merck, Abbvie, Medimmune, Novartis, Roche-Genentech, Amgen, Tenebio, Carsgen. He also participates in consulting/advisory boards (with no personal payments) for the following: Celgene, Takeda, Janssen, KITE, Merck, Abbvie, Medimmune, Genentech, Amgen, Molecular Partners and (with personal payment) Oncopeptides, Adaptive, Genecentrix.
- Dr. John Hagan, a reviewer for our March 2020 article on sinus problems, has participated in research trials of the drug Dupilumab (Dupixent).
- Dr. Francisco Lopez-Jimenez, a reviewer for our October 2020 article on artificial intelligence and health care is listed as coinventor of several applications for patents using AI in cardiology.
- Dr. Bradley Erickson, a reviewer for our October 2020 article on artificial intelligence and health care is founder of a company (FlowSIGMA) that orchestrates the execution of AI tools.
- Gastroenterologist Michael Camilleri M.D., a reviewer for our November 2020 Second Opinion on bile acid diarrhea, has no financial conflict of interest but his research is funded by NIH RO1 DK 115950 and he has received research funding related to clinical trials on bile acid diarrhea (BAD) from Novartis (tropifexor) and Allergan (eluxadoline).
- Eric J. Moore, M.D., who was a reviewer for our February 2021 article on Head and Neck cancer, has received honorarium for educational conferences from Intuitive Surgical.
- Brooke M. Katzman, Ph.D., who was a reviewer for our February 2021 article on biotin and medical test interference, has received honoraria for speaking engagements and for participating in an advisory board for Roche Diagnostics, however that has not occurred within the last 12 months.
- Amaal Starling, M.D., who was a reviewer for our June 2021 article on migraines has received consulting fees on the topic of migraine from Allergan, Amgen, Axsome Therapeutics, Eli Lilly & Company, Everyday Health, Impel, Lundbeck, Med-IQ, Medscape, Novartis, Satsuma, Teva, and Theranica.
- Prasad G. Iyer, M.D., who was a reviewer for our Sept. 2021 article on Barrett's esophagus has received research funding from Exact Sciences and Pentax medical, and is a consultant for Medtronic and Ambu.